Healthcare

According to the statement, CSL was notified late in the afternoon of Wednesday 21 October 2026 that the proceeding had been lodged, and that it names CSL as the defendant. The announcement is brief and sets out the basic features of the claim, the …

The regenerative medicine company said global revenue from its nerve repair product Remplir rose 20% on the previous quarter and now accounts for more than 40% of total quarterly revenue. US Remplir revenue reached $0.40 million.

The committee examined safety, tolerability and pharmacokinetic information from Cohort 1 and recommended that the study move forward at a dose set under its predefined dose-escalation design. Recruitment for Cohort 2 is expected to commence shortly, and the company has stated that it remains …

Managing Director Dr Daniel Tillett said the company is funded to continue advancing RC220 into mid-CY2028, and the quarter included trial expansion into South Korea and additional ethics approvals for sites in New South Wales and Victoria.

Under the terms, Arrotex obtains exclusive commercialization rights in both countries, while Recce remains the exclusive manufacturer and supplier of the product. Recce will receive what it describes as a significant profit share of gross margin from product sales. The agreement is binding and …

The quarterly activities report and Appendix 4C describe progress on the company's lead radiopharmaceutical program, a change in its stake in Petalion Therapeutics and continued work with two licensing partners.

The arrangement follows the clinical development update that TrivarX issued to the market on 23 September 2026. That update set out progress across the workstreams needed to move Stabl-Im into clinical evaluation, namely investigational product formulation, analytical methodology development, dosing protocols and clinical study …